Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04659317 · ClinicalTrials.gov registry record · Phase 3

Opioid-Free Orthopaedics

A Phase 3 study of Pain and Pain, Postoperative, sponsored by Emory University.

Recruiting
Registry status
Phase 3
Development phase
80
Enrollment target
3
Study locations

NCT04659317 is a Phase 3 study of Pain and Pain, Postoperative that is actively recruiting participants, run by Emory University. The registered enrollment target is 80 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04659317, a Phase 3 study of Pain and Pain, Postoperative, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 3
Development phase
80 participants
Enrollment target
3
Study locations

Study Summary

The goal of this investigation is to compare effectiveness of this multimodal regimen at controlling postoperative pain with and without the use of opioid medications.

Conditions Studied

Interventions

  • DRUG Placebo oral tablet
  • DRUG Oxycodone 5 mg Oral Tablet

Study Locations (3)

Georgia

  • The Emory Clinic - Atlanta
  • Emory University Hospital - Atlanta
  • Emory Orthopedic and Spine Hospital - Tucker

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2020-12-11
Est. Completion 2028-12
Phase Phase 3

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT04659317

The ClinicalTrials.gov registry entry for NCT04659317 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.

NCT04659317 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT04659317 about?

NCT04659317 is a clinical study titled "Opioid-Free Orthopaedics". The goal of this investigation is to compare effectiveness of this multimodal regimen at controlling postoperative pain with and without the use of opioid medications.

What is the current status of trial NCT04659317?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2020-12-11. Estimated completion is 2028-12.

What conditions does trial NCT04659317 study?

This clinical trial studies the following conditions: Pain, Pain, Postoperative.

What interventions are being tested in trial NCT04659317?

The interventions under investigation include: Placebo oral tablet (DRUG), Oxycodone 5 mg Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT04659317?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04659317 being conducted?

This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.